Novilla
Novilla develops AI-designed localized therapeutics to treat pain and inflammation by targeting specific tissues and minimizing systemic side effects. The company's mission is to transform pain care and reduce opioid-related risks by enabling effective, site-specific treatments. Novilla integrates expertise in drug delivery, chemical thermodynamics, and machine learning to address indications such as gout, diabetic circulatory insufficiency, joint inflammation, muscle spasms, and postoperative pain.
Industries
N/A
Novilla
Patents
Products
A pain therapeutic developed using AI algorithms for localized action, showing increased efficacy and minimal systemic exposure in clinical trials.
A pain therapeutic developed using AI algorithms for localized action, showing increased efficacy and minimal systemic exposure in clinical trials.
Expertise Areas
- Local drug delivery for pain management
- AI-assisted therapeutic discovery
- Clinical evaluation of localized therapeutics
- Non-opioid pain and inflammation therapies
Key Technologies
- Machine learning for drug design
- Chemical thermodynamics in formulation
- Precision drug delivery systems
- Analytical chemistry methods
Key People
Chief Executive Officer
Vice President of Product Development
Managing Director
Chairman to the Scientific Advisory Board
Co-Founder
Senior Research Associate
Chief Executive Officer
Vice President of Product Development
Managing Director
Chairman to the Scientific Advisory Board
Co-Founder
Senior Research Associate
News & Updates
First-in-human clinical trial demonstrated a 212% increase in efficacy versus standard of care with less than 1% systemic exposure and no GI adverse events.
Formulation with hydrofluoroalkane propellant and dihydroergotamine mesylate particles for targeted delivery.
Non-invasive technique for non-systemic delivery of analgesics to neural regions for pain relief.
First-in-human clinical trial demonstrated a 212% increase in efficacy versus standard of care with less than 1% systemic exposure and no GI adverse events.
Formulation with hydrofluoroalkane propellant and dihydroergotamine mesylate particles for targeted delivery.
Non-invasive technique for non-systemic delivery of analgesics to neural regions for pain relief.